Venclexta safety warnings in multiple myeloma patients
US regulators have posted a safety statement warning of an increased risk of death for patients receiving AbbVie’s venetoclax with bortezomib and dexamethasone for melanoma patients.
Read More
Tag: BELLINI
FDA places partial hold on clinical trials of venetoclax for multiple myeloma
US regulators have placed a partial clinical hold on all trials assessing venetoclax for multiple myeloma after a higher than expected number of patient deaths.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
